The treatment goals and lipid thresholds for initiating drug therapy are based on the presence of CHD and number of risk factors. Several lipid-modifying agents including statins, fibrates, niacin have shown the ability to reduce cardiovascular events in randomized clinical outcome trials.

This video talks about the newer drugs coming in the market for lipid management.